Nuvectis Pharma reported a net loss of $7.0 million for the second quarter ended June 30, 2026, compared to $6.3 million in the prior year period. The company completed a follow-on public offering in July 2026, raising $115 million in gross proceeds and extending its cash runway into the first half of 2029. Cash and cash equivalents stood at $22.2 million as of June 30, 2026. The firm also announced the in-licensing of ex-China rights to two compounds, NXP100 (ciprocopan) and NXP200, from Haisco Pharmaceutical Group. Ciprocopan received marketing approval in China in July 2026 for treating paroxysmal nocturnal hemoglobinuria. The company operates as a clinical-stage biopharmaceutical firm developing therapies for complement-related conditions and oncology.
